What patents exist for levonorgestrel + ethinylestradiol, and who holds them?
Patents for levonorgestrel combined with ethinylestradiol typically cover specific formulations (dose forms and release characteristics), manufacturing processes, and sometimes particular fixed-dose combinations or dosing regimens used in certain branded oral contraceptives. These rights are held by drug manufacturers, and ownership depends on the exact product (brand name) and the jurisdiction where a patent is filed.
If you share the brand name (or the country you care about), I can narrow this to the most relevant patent(s) and explain what the claims usually cover.
When do patents for levonorgestrel + ethinylestradiol expire?
Patent expiration depends on:
- the filing date (and whether patents were granted),
- whether there were extensions such as patent term extensions (where applicable),
- and the jurisdiction (US, EU/EMA member states, UK, etc.).
Fixed-dose oral contraceptive combinations are often older, so many foundational patents may already be expired in many markets, but newer patents can still exist for particular formulations (for example, specific tablet types or improved stability/release profiles) even after earlier “core” patents lapse.
Can generic or biosimilar versions enter before patent expiry?
For this specific combination (a small-molecule oral contraceptive), generic manufacturers generally seek approval via generic pathways once they can legally reference a comparable product and once relevant exclusivities/patents are no longer blocking entry. In practice, the timing depends on:
- which patents are still active in that country,
- whether patents block the exact dosage form being filed, and
- whether regulatory exclusivities (separate from patents) apply.
Why do “same ingredients” products still have different patent timelines?
Two products can both contain levonorgestrel + ethinylestradiol but still fall under different patent coverage if they differ in:
- tablet formulation (inactive ingredients, coatings, hardness, stability),
- release characteristics (immediate vs modified),
- dose strength (microgram content),
- or the specific combination pack/dosing schedule.
That is why patent landscape searches are usually product- and country-specific rather than ingredient-only.
What to look for in a patent search for this combination
A targeted search typically includes:
- the exact drug combination terms (levonorgestrel + ethinylestradiol),
- synonyms (and brand name mappings),
- “combination drug product” wording,
- the listed dosage form (tablet) and strength,
- and the assignee/holder.
What do patents typically cover for oral contraceptive combinations like this?
Common patent categories include:
- fixed-dose combination compositions (the exact proportions),
- formulation and manufacturing improvements,
- stability/packaging-related improvements,
- and sometimes methods of use (though composition/formulation claims tend to matter most for generic entry).
If you tell me the country and brand, can you identify the relevant patents?
Yes. To give a precise answer, tell me:
1) the country (e.g., US, UK, Spain, France, Germany),
2) the brand name or dose strength (e.g., “levonorgestrel 0.15 mg + ethinylestradiol 0.03 mg”),
3) whether you want “all patents” or only the ones that could block generic entry.
Sources:
No sources were provided in the prompt, so I can’t cite specific patents or dates yet.